Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide

Journal of Infectious Diseases

Volumn 213, Issue 4, 2016, Pages 640-648

  Thaden, Joshua T ^a   Keller, Ashley E ^b   Shire, Norah J ^b   Camara, M Margarita ^b   Otterson, Linda ^c   Huband, Mike ^c   Guenther, Caitlin M ^b   Zhao, Wei ^b   Warrener, Paul ^b   Stover, C Kendall ^b   Fowler, Vance G ^a   DiGiandomenico, Antonio ^b  

^a DUKE UNIVERSITY   (United States)

^b MEDIMMUNE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

bacteremia; bispecific antibody; prophylaxis; Pseudomonas aeruginosa; Psl exopolysaccharide; type 3 secretion

Indexed keywords

BACTERIAL PROTEIN; EXOPOLYSACCHARIDE; IMMUNOGLOBULIN G; PROTEIN PCRV; PROTEIN PSL; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; OPSONIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TYPE III SECRETION SYSTEM; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BACTEREMIA; BLOOD; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MOUSE; PROSPECTIVE STUDY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, BACTERIAL; BACTEREMIA; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPSONIN PROTEINS; PHAGOCYTOSIS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84960172056     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv436     Document Type: Article

References (34)

1. Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10: 629-35
2. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17: 701-8
3. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001. Antimicrob Agents Chemother 2003; 47: 1681-8
4. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606-10
5. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-21
6. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015; 19: 219
7. Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009; 77: 1083-90
8. Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2014; 49: 650-8
9. Francois B, Luyt CE, Dugard A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebocontrolled trial. Crit Care Med 2012; 40: 2320-6
10. Song Y, Baer M, Srinivasan R, et al. PcrV antibody-Antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis 2012; 31: 1837-45
11. Warrener P, Varkey R, Bonnell JC, et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 2014; 58: 4384-91
12. Sawa T, Yahr TL, Ohara M, et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999; 5: 392-8
13. DiGiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014; 6: 262ra155
14. DiGiandomenico A, Warrener P, Hamilton M, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med 2012; 209: 1273-87
15. Mishra M, Byrd MS, Sergeant S, et al. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell Microbiol 2012; 14: 95-106
16. Zhao K, Tseng BS, Beckerman B, et al. Psl trails guide exploration and microcolony formation in Pseudomonas aeruginosa biofilms. Nature 2013; 497: 388-91
17. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, Lory S. A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa. Dev Cell 2004; 7: 745-54
18. Howell HA, Logan LK, Hauser AR. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 2013; 4: e00032-13
19. Mikkelsen H, Sivaneson M, Filloux A. Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ Microbiol 2011; 13: 1666-81
20. Ventre I, Goodman AL, Vallet-Gely I, et al. Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes. Proc Natl Acad Sci U S A 2006; 103: 171-6
21. Cockerill FR, Wikler MA, Alder J, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. Wayne, PA: Clinical and Laboratory Standard Institute, 2012
22. DiGiandomenico A, Rao J, Harcher K, et al. Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2007; 104: 4624-9
23. Franklin MJ, Nivens DE, Weadge JT, Howell PL. Biosynthesis of the Pseudomonas aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl. Front Microbiol 2011; 2: 167
24. Byrd MS, Sadovskaya I, Vinogradov E, et al. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol Microbiol 2009; 73: 622-38
25. Lynch SV, Flanagan JL, Sawa T, et al. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV-implications for anti-PcrV immunotherapy. Microb Pathog 2010; 48: 197-204
26. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183: 1767-74
27. Li H, Mo KF, Wang Q, Stover CK, DiGiandomenico A, Boons GJ. Epitope mapping of monoclonal antibodies using synthetic oligosaccharides uncovers novel aspects of immune recognition of the Psl exopolysaccharide of Pseudomonas aeruginosa. Chemistry 2013; 19: 17425-31
28. Corech R, Rao A, Laxova A, et al. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis. J Clin Microbiol 2005; 43: 3956-62
29. Milagres LG, Castro TL, Garcia D, et al. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis. Pediatr Pulmonol 2009; 44: 392-401
30. Moss J, Ehrmantraut ME, Banwart BD, Frank DW, Barbieri JT. Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus. Infect Immun 2001; 69: 1185-8
31. Kronborg G, Shand GH, Fomsgaard A, Hoiby N. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS 1992; 100: 175-80
32. MacDougall J, Hodson ME, Pitt TL. Antibody response of fibrocystic patients to homologous 0-Typable and 0-defective isolates of Pseudomonas aeruginosa. J Clin Pathol 1990; 43: 567-71
33. Anstead M, Heltshe SL, Khan U, et al. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. J Cyst Fibros 2013; 12: 147-53
34. Kappler M, Nagel F, Feilcke M, et al. Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment. J Cyst Fibros 2014; 13: 534-41